Turning on Tregs

How Delinia is threading the IL-2 needle in autoimmunity

Although expanding Tregs to treat autoimmune diseases offers a safer alternative to general immunosuppression, the challenge has been to target only those cells, and avoid stimulating T cells that will exacerbate disease. By homing in a form of the IL-2 receptor only on Tregs, Delinia Inc. has carved a way to potentiate the suppressive pathway alone.

Delinia was launched earlier this year to develop

Read the full 633 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE